Trial Search Results
Neural Signatures of Parkinson's Disease
The purpose of this study is to provide objective measurements of abnormal movements of the body in correlation with neural activity of the brain and track how these change over time. This may allow for the development of objective evaluation of the neural activity causing abnormal movements, which may lead to the ability of the DBS system to stimulate the brain by sensing the abnormal neural activity that is causing abnormal movements.
Stanford is currently accepting patients for this trial.
- Device: Activa PC+S
- a diagnosis of idiopathic Parkinson's disease, with bilateral symptoms at Hoehn and
Yahr Stage greater than or equal to II.
- Documented improvement in motor signs on versus off dopaminergic medication, with a
change in the Unified Parkinson's Disease Rating Scale motor (UPDRS III) score of >=
30% off to on medication.
- The presence of complications of medication such as wearing off signs, fluctuating
responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment
in the quality of life on or off medication due to these factors.
- Subjects should be on stable doses of medications, which should remain unchanged until
the DBS system is activated. After the DBS system is optimized (during which time the
overall medication dose may be reduced to avoid discomfort and complications such as
dyskinesias) the medication dose should remain unchanged, if possible, for the
duration of the study.
- Treatment with carbidopa/levodopa, and with a dopamine agonist at the maximal
tolerated doses as determined by a movement disorders neurologist.
- Ability and willingness to return for study visits, at the initial programming and
after three, six and twelve months of DBS.
- Age > 18
- Subjects with significant cognitive impairment and/or dementia as determined by a
standardized neuropsychological battery.
- Subjects with clinically active depression, defined according to the Diagnostic and
Statistical manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and as scored
on a validated depression assessment scale.
- Subjects with very advanced Parkinson's disease, Hoehn and Yahr stage 5 on medication
- Age > 80.
- Subjects with an implanted electronic device such as a neurostimulator, cardiac
pacemaker/defibrillator or medication pump.
- Subjects, who are pregnant, are capable of becoming pregnant, or who are breast
- Patients with cortical atrophy out of proportion to age or focal brain lesions that
could indicate a non-idiopathic movement disorder as determined by MRI
- Subjects having a major comorbidity increasing the risk of surgery (prior stroke,
severe hypertension, severe diabetes, or need for chronic anticoagulation other than
- Subjects having any prior intracranial surgery.
- Subjects with a history of seizures.
- Subjects, who are immunocompromised.
- Subjects with an active infection.
- Subjects, who require diathermy, electroconvulsive therapy (ECT), or transcranial
magnetic stimulation (TMS) to treat a chronic condition.
- Subjects, who have an inability to comply with study follow-up visits.
- Subjects, who are unable to understand or sign the informed consent
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study